Clinical trials: SARS-COV-2 Infection
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19, Influenza
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent…
- Trial name
- COVID-19 (NCT05519839)
- Testing
- qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant
- Where
- 35 sites in Australia, New Zealand
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV2 Infection
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine
This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation
- Trial name
- COVID-19 (NCT04508075)
- Testing
- SARS-CoV-2 vaccine (inactivated)
- Where
- Indonesia
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.
- Trial name
- NCT05329051
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
Covid19
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic…
- Trial name
- CoronaStem1 (NCT04486001)
- Testing
- PSC-04
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
ARDS, Human, Covid19
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV…
- Trial name
- RECOVER (NCT04629105)
- Testing
- Longeveron Mesenchymal Stem Cells (LMSCs)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Longeveron Inc.
Covid-19
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
- Trial name
- NCT06016556
- Testing
- nirmatrelvir, ritonavir
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 250 people
- Sponsor
- Pfizer
Covid19
Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.
This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo and BAT for the treatment of Moderate to Severe…
- Trial name
- NCT04900337
- Testing
- AMOR 18 Powder & Inhalation
- Where
- 3 sites in Israel
- Volunteers
- 66 people
- Sponsor
- Amorphical Ltd.
COVID-19 Respiratory Infection
Bifido- and Lactobacilli in Symptomatic Adult COVID-19 Outpatients
There is evidence that some types of probiotics play a role in alleviation of symptoms of acute respiratory tract infections and bursting immune response to respiratory and enteric viruses.
- Trial name
- ProCOVID (NCT04907877)
- Testing
- Probiotic
- Where
- 3 sites in Ukraine
- Volunteers
- 70 people
- Sponsor
- Nordic Biotic Sp. z o.o.
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior.
- Trial name
- NCT04816669
- Testing
- BNT162b2
- Where
- 21 sites in United States
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
Viral Respiratory Tract Infection
Safety and Tolerability of Single and Multiple Doses of Neumifil
This is a Phase 1, single-centre, randomised, placebo-controlled first in human study in healthy subjects. The study will assess the safety and tolerability of single-ascending (Part A) and multiple-ascending (Part B) doses of…
- Trial name
- NCT05093530
- Testing
- Neumifil
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pneumagen Ltd.
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
COVID - 19, Influenza A
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection.
- Conditions
- COVID - 19, Influenza A, Influenza B
- Trial name
- NCT07190131
- Testing
- Investigational Flu A/B And Covid-19 Diagnostic Test
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 588 people
- Sponsor
- iHealth Labs inc
Covid19
Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients
The SaiseiCovUKR clinical study is a multicentric, randomized trial study targeting patients hospitalized with COVID-19 who do not require mechanical ventilation.
- Trial name
- SaiseiCovUKR (NCT04762628)
- Testing
- MAF capsules 148 mg, M capsules 148 mg, Standard of care
- Where
- 2 sites in Ukraine
- Volunteers
- 600 people
- Sponsor
- Saisei Pharma
Covid19
Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection
It has been reported in several research studies that men are almost twice as likely to progress to severe COVID 19 disease and die than women.
- Trial name
- NCT04801836
- Testing
- Estetrol monohydrate 15 mg
- Where
- 25 sites in Belgium, Hungary and 2 more
- Volunteers
- 162 people
- Sponsor
- NEURALIS s.a.
COVID-19
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
The phase Ⅱ trial adopts a randomized, double-blind, placebo-controlled design to evaluate the immunogenicity and safety profile of LYB001 in healthy adults aged 18 years and older.
- Trial name
- NCT05137444
- Testing
- LYB001
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.